BIIB Biogen
Flat $10B neuroscience incumbent priced for a pipeline payoff it hasn't yet earned.
The story
Biogen is a neuroscience franchise whose legacy MS portfolio (Tecfidera, Tysabri) keeps eroding to generics and biosimilars, while growth bets (Leqembi in Alzheimer's, Skyclarys, Zurzuvae, rare disease) are only slowly filling the gap. Revenue has flattened at about $10B as new launches offset MS declines, but the company is a mature, cash-generative pharma whose upside depends on whether its Alzheimer's and pipeline bets scale profitably. It is in late maturity with an option-like pipeline, not a durable-growth franchise.
No material facts changed since September. TTM revenue of $10.03B (slightly up) supports roughly 2% near-term growth. The drop in TTM margin to 12.9% looks driven by acquired IPR&D and one-off charges rather than a lasting change in economics, so the 19% target stays in line with the 18 to 22% normalized history. Sales-to-capital of 0.4 matches the reported 0.41 and reflects capital-heavy, acquisition-led reinvestment.
Value drivers
| Revenue growth (Y1) | 2.0% |
| Terminal growth | 1.0% |
| Forecast horizon | 7y |
| Target operating margin | 19.0% |
| Years to target margin | 7 |
| Sales-to-capital | 0.40 |
| Beta | 1.05 |
| Failure probability | 4.0% |
| Cost of capital (WACC) | 9.4% |
| Terminal WACC | 9.2% |
Valuation bridge
| PV of explicit FCFF | 5.08B |
| PV of terminal value | 10.28B |
| Equity value | 11.60B |
| ÷ shares → per share | $78.51 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 10.23B | 2.0% | 13.8% | 1.17B | 501.39M | 670.55M | 612.97M |
| 2 | 10.42B | 1.8% | 14.7% | 1.27B | 468.80M | 799.70M | 668.27M |
| 3 | 10.59B | 1.7% | 15.5% | 1.37B | 434.00M | 931.97M | 711.94M |
| 4 | 10.75B | 1.5% | 16.4% | 1.46B | 397.11M | 1.07B | 744.98M |
| 5 | 10.89B | 1.3% | 17.3% | 1.56B | 358.28M | 1.20B | 768.38M |
| 6 | 11.02B | 1.2% | 18.1% | 1.66B | 317.68M | 1.34B | 783.08M |
| 7 | 11.13B | 1.0% | 19.0% | 1.76B | 275.47M | 1.48B | 790.01M |
Key risks
- Leqembi and subcutaneous uptake stall from diagnostic, infusion and reimbursement friction or competition from Lilly's Kisunla
- MS erosion speeds up (Tysabri biosimilars, Vumerity/Tecfidera generics) faster than launches can replace it
- Expensive M&A or pipeline failures (lupus, ALS, tau programs) that destroy capital
Catalysts
- Leqembi subcutaneous maintenance and initiation dosing approvals driving an inflection in patient starts
- Pivotal readouts in lupus (litifilimab, dapirikizumab) or anti-tau programs that broaden the growth story beyond MS